Agilent Technologies

A Health Care Market cap $41.5B as of Sep 14, 2026 16:02 ET S&P 500

Q3 FY26 May 1 – Jul 31, 2026 reported Sep 1, 2026

Revenue$1.88B +8% year over year

Gross profit$1.04B 55% margin

Operating profit$0.44B 24% margin

Net profit$0.36B 19% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q3 FY26 (period ends Jul 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.88	100%	+8%
Non-Instrumentation	1.22	65%
Instrumentation	0.62	33%	+3%
Other	0.04	2%
Cost of revenue	−0.84	45%
Gross profit	1.04	55% margin	+4pp
R&D	−0.12	7%	+0pp
SG&A	−0.48	25%	+1pp
Operating profit	0.44	24% margin	+3pp
Tax	−0.08
Net profit	0.36	19% margin	+0pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Apr 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.84	100%	+10%
Non instrumentation	1.22	66%	+9%
Instrumentation	0.62	34%	+12%
Cost of revenue	−0.85	46%
Gross profit	0.99	54% margin	+2pp
R&D	−0.13	7%	+0pp
SG&A	−0.47	25%	−2pp
Operating profit	0.40	22% margin	+4pp
Tax	−0.06
Net profit	0.34	18% margin	+6pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Jan 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	1.80	100%	+7%
Non instrumentation	1.14	63%	+8%
Instrumentation	0.66	37%	+5%
Cost of revenue	−0.85	47%
Gross profit	0.95	53% margin	−1pp
R&D	−0.12	7%	+0pp
SG&A	−0.48	26%	+2pp
Operating profit	0.35	20% margin	−3pp
Other income, net	0.01
Tax	−0.06
Net profit	0.31	17% margin	−2pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Oct 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.86	100%	+9%
Non instrumentation	1.21	65%	+12%
Instrumentation	0.65	35%	+5%
Cost of revenue	−0.87	47%
Gross profit	0.99	53% margin	−1pp
R&D	−0.12	6%	+0pp
SG&A	−0.43	23%	+0pp
Operating profit	0.44	24% margin	+0pp
Tax	−0.01
Net profit	0.43	23% margin	+3pp

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Jul 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	1.74	100%	+10%
Non instrumentation	1.14	66%	+11%
Instrumentation	0.60	34%	+8%
Cost of revenue	−0.85	49%
Gross profit	0.89	51% margin	−3pp
R&D	−0.11	6%	−2pp
SG&A	−0.42	24%	−1pp
Operating profit	0.36	21% margin	+0pp
Tax	−0.02
Net profit	0.34	19% margin	+1pp

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q3 FY26 May 1 – Jul 31, 2026 reported Sep 1, 2026 Operating margin 24% Net profit $0.36B	May 1 – Jul 31, 2026	Sep 1, 2026	$1.88B	+8%	24%	$0.36B	19%
Q2 FY26 Feb 1 – Apr 30, 2026 reported Jun 1, 2026 Operating margin 22% Net profit $0.34B	Feb 1 – Apr 30, 2026	Jun 1, 2026	$1.84B	+10%	22%	$0.34B	18%
Q1 FY26 Nov 1, 2025 – Jan 31, 2026 reported Mar 3, 2026 Operating margin 20% Net profit $0.31B	Nov 1, 2025 – Jan 31, 2026	Mar 3, 2026	$1.80B	+7%	20%	$0.31B	17%
Q4 FY25 Aug 1 – Oct 31, 2025 reported Dec 22, 2025 Operating margin 24% Net profit $0.43B	Aug 1 – Oct 31, 2025	Dec 22, 2025	$1.86B	+9%	24%	$0.43B	23%
Q3 FY25 May 1 – Jul 31, 2025 reported Aug 29, 2025 Operating margin 21% Net profit $0.34B	May 1 – Jul 31, 2025	Aug 29, 2025	$1.74B	+10%	21%	$0.34B	19%